- Home
- OMCL vs SLNO Comparison
OMCL vs SLNO Comparison
Compare OMCL & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- SLNO
- Stock Information
- Founded
- OMCL 1992
- SLNO 1999
- Country
- OMCL United States
- SLNO United States
- Employees
- OMCL N/A
- SLNO N/A
- Industry
- OMCL Computer Manufacturing
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- OMCL Technology
- SLNO Health Care
- Exchange
- OMCL Nasdaq
- SLNO Nasdaq
- Market Cap
- OMCL 2.0B
- SLNO 1.9B
- IPO Year
- OMCL 2001
- SLNO 2014
- Fundamental
- Price
- OMCL $44.98
- SLNO $45.18
- Analyst Decision
- OMCL Buy
- SLNO Strong Buy
- Analyst Count
- OMCL 6
- SLNO 6
- Target Price
- OMCL $52.00
- SLNO $74.83
- AVG Volume (30 Days)
- OMCL 634.2K
- SLNO 788.7K
- Earning Date
- OMCL 02-06-2025
- SLNO 11-06-2024
- Dividend Yield
- OMCL N/A
- SLNO N/A
- EPS Growth
- OMCL N/A
- SLNO N/A
- EPS
- OMCL N/A
- SLNO N/A
- Revenue
- OMCL $1,064,205,999.00
- SLNO N/A
- Revenue This Year
- OMCL N/A
- SLNO N/A
- Revenue Next Year
- OMCL $5.24
- SLNO N/A
- P/E Ratio
- OMCL N/A
- SLNO N/A
- Revenue Growth
- OMCL N/A
- SLNO N/A
- 52 Week Low
- OMCL $25.12
- SLNO $35.70
- 52 Week High
- OMCL $55.75
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- OMCL 46.41
- SLNO 32.12
- Support Level
- OMCL $43.29
- SLNO $43.32
- Resistance Level
- OMCL $47.00
- SLNO $48.51
- Average True Range (ATR)
- OMCL 1.55
- SLNO 2.09
- MACD
- OMCL -0.27
- SLNO -0.38
- Stochastic Oscillator
- OMCL 37.31
- SLNO 20.44
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.